1.45
-0.05(-3.33%)
Currency In USD
| Previous Close | 1.5 |
| Open | 1.51 |
| Day High | 1.51 |
| Day Low | 1.43 |
| 52-Week High | 4.07 |
| 52-Week Low | 0.81 |
| Volume | 183,072 |
| Average Volume | 401,130 |
| Market Cap | 15.66M |
| PE | -1.24 |
| EPS | -1.17 |
| Moving Average 50 Days | 1.62 |
| Moving Average 200 Days | 1.31 |
| Change | -0.05 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $18.59 as of February 21, 2026 at a share price of $1.45. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $54.72 as of February 21, 2026 at a share price of $1.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
GlobeNewswire Inc.
Jan 26, 2026 12:00 PM GMT
National broadcast highlights the need for new approaches in one of the deadliest forms of cancerHOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclus
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit an